Aetna considers the test "medically necessary" and the decision opens the door for 19 million people to access the risk classifier test.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
The in-network contracts provide coverage for insured patients in Connecticut, Maine, and New Hampshire for both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company said the agreement will make its cancer diagnostics and genomic tests available to more than 2.6 million people.
NantHealth is also planning to launch a 20,000-patient multi-arm, multi-drug trial based on profiling patients' tumors with its GPS Cancer test.
The coverage is for Paradigm's PCDx test, and will extend to all patients insured by UnitedHealthcare throughout the United States.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.